Target intelligence / Profile preview

Alpha-centractin (ACTR1A)

Target
ACTR1A
Molecular classification
Actin-related protein, structural/cytoskeletal complex protein
01

Overview

Alpha-centractin (ACTR1A) is a highly conserved actin-related protein that serves as the major structural subunit of the dynactin complex, a multi-protein assembly crucial for intracellular transport by linking cytoplasmic dynein to its cargo[1][2][3][5]. ACTR1A is present as 8–13 copies per dynactin complex and forms a filamentous core, sharing about 60% amino acid identity with conventional actin[1][2][5]. The dynactin complex, through ACTR1A, is vital for multiple cellular processes such as ER-to-Golgi transport, lysosome and endosome movement, mitotic spindle formation, chromosome movement, nuclear positioning, and axonogenesis[1][3][5]. Apart from its canonical cytoskeletal and transport functions, ACTR1A has been implicated in immune regulation (notably as a TLR2 signal cascade regulator) and may play a role in tumorigenesis as genetic alterations have been observed in certain cancers[3]. No drugs currently target ACTR1A directly, and it is not generally considered a therapeutic target[1][3][5].

Other names
Arp1ARP1 actin-related protein 1 homolog ACTRN1CentractinARP1Aactin-RPVcentrosome-associated actin homologcentractin alphaepididymis secretory sperm binding protein
02

Mechanism of action

Not applicable (no drugs target ACTR1A directly)

03

Biological functions

Cytoskeletal organizationIntracellular transport (dynein/dynactin-dependent)Organelle positioningSpindle formationChromosome movementAxonogenesisImmune regulation (modulation of TLR2 signaling)
04

Disease associations

Cancer (e.g., mutations in malignant pleural mesothelioma)Potential roles in immune-related disease
05

Safety considerations

None specifically documentedtheoretical concern relates to disruption of essential cellular transport and division functions if inhibited
06

Biomarkers

None establishedpossible relevance in cancer genomics studies (e.g., malignant mesothelioma)

Beyond the preview

Go deeper on Alpha-centractin (ACTR1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-centractin (ACTR1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call